Difficulty: Medium
Average Score: 76%
Practice
Avoidance of triggering agents is crucial in urticaria and angioedema. The MAINSTAY of pharmacologic treatment is
Correct answer
A
Rationale
In the management of urticaria and angioedema, avoidance of triggering agents is essential to prevent exacerbations. The mainstay of pharmacologic treatment for these conditions is second-generation H1 antihistamines, making option A the correct choice.
Second-generation H1 antihistamines, such as loratadine, cetirizine, and fexofenadine, are preferred due to their decreased sedative effects compared to first-generation antihistamines. They work by blocking the action of histamine, which is responsible for the symptoms of urticaria and angioedema.
Tricyclic antidepressants (option B) are not recommended as first-line treatment for urticaria and angioedema. They may be considered in some cases for their antihistaminic effects, but their side effect profile and potential for drug interactions make them less favorable.
Corticosteroids (option C) are not typically used as the mainstay treatment for urticaria and angioedema due to their potential for long-term adverse effects and limited efficacy in these conditions.
Leukotriene receptor blockers (option D) are more commonly used in conditions like asthma and allergic rhinitis, but they are not considered first-line treatment for urticaria and angioedema.
In an educational context, understanding the appropriate pharmacologic management of urticaria and angioedema is crucial for pediatric clinical nurse specialists to provide optimal care to their patients. By recognizing the mainstay of treatment and the rationale behind it, nurses can effectively manage these conditions and improve patient outcomes.
Second-generation H1 antihistamines, such as loratadine, cetirizine, and fexofenadine, are preferred due to their decreased sedative effects compared to first-generation antihistamines. They work by blocking the action of histamine, which is responsible for the symptoms of urticaria and angioedema.
Tricyclic antidepressants (option B) are not recommended as first-line treatment for urticaria and angioedema. They may be considered in some cases for their antihistaminic effects, but their side effect profile and potential for drug interactions make them less favorable.
Corticosteroids (option C) are not typically used as the mainstay treatment for urticaria and angioedema due to their potential for long-term adverse effects and limited efficacy in these conditions.
Leukotriene receptor blockers (option D) are more commonly used in conditions like asthma and allergic rhinitis, but they are not considered first-line treatment for urticaria and angioedema.
In an educational context, understanding the appropriate pharmacologic management of urticaria and angioedema is crucial for pediatric clinical nurse specialists to provide optimal care to their patients. By recognizing the mainstay of treatment and the rationale behind it, nurses can effectively manage these conditions and improve patient outcomes.